Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Oral Arsenic Trioxide (Arsenol ®)-Based Low-intensity Treatment for Previously Untreated or Relapsed/Refractory TP53-mutated Myeloid Malignancies

NCT06778187 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT06778187
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06778187 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Oral Arsenic Trioxide (Arsenol ®)-Based Low-intensity Treatment for Previously Untreated or Relapsed/Refractory TP53-mutated Myeloid Malignancies
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Recruiting
Start date
February 7, 2025
Completion date
February 29, 2028
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, arsenic trioxide, chronic myelomonocytic leukemia, myelodysplastic neoplasm, tp53 gene mutation